NDA 213978 · Harrow Eye
Tyrvaya
Varenicline Tartrate · Nasal
Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Oct 15, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
336
68 Phase 3, 23 recruiting
FAERS reports
6,231
1,606 serious, 71 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 10, 2026.
TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )
Mechanism: The efficacy of TYRVAYA in dry eye disease is believed to be the result of varenicline's activity at heteromeric sub-type(s) of the nicotinic acetylcholine (nACh) receptor where its binding produces agonist activity and activates the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease. Varenicline binds with high affinity and selectivity at human α4β2, α4α6β2, α3β4, α3α5β4 and α7 neuronal nicotinic acetylcholine receptors. The exact mechanism of action is unknown at this time.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TYRVAYA · VARENICLINE TARTRATE EQ 0.03MG BASE/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Varenicline" as an intervention, any sponsor and status, largest first.
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I TrialPivotal-lookingRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04604509 · 2,010 participants (planned) · Start Aug 4, 2020 · Primary completion Dec 31, 2028
Drug: Bupropion Hydrochloride Controlled-release; Nicotine Replacement and 1 more · For: Cigarette Smoking-Related Carcinoma
Sites: Houston, Texas
- A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking CessationPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00143286 · 2,000 participants · Start Apr 2003
Drug: varenicline (CP-526,555) · For: Smoking Cessation
Sites: Santa Ana, California; West Palm Beach, Florida; Lexington, Kentucky · 24 sites in all
- Risk Reduction in Coronary Heart DiseasePivotal-lookingCompleted
Sorlandet Hospital HFGovernment (non-federal)
NCT00679237 · 1,600 participants · Start Sep 2007 · Primary completion Dec 2019
Drug: betablocker, diuretics, ACEI, ARB,; statins, ezetimibe and 2 more · For: Coronary Heart Disease
Sites: Arendal, Norway
- A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through ReductionPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01370356 · 1,510 participants · Start Jul 2011 · Primary completion Jul 2013
Drug: Varenicline Tartrate; Placebo · For: Smoking Cessation
Sites: Encino, California; Newport Beach, California; Jacksonville, Florida · 65 sites in all
- UW Quitting Using Intensive Treatment Study (QUITS)Pivotal-lookingCompleted
University of Wisconsin, MadisonAcademic, hospital or other
NCT03176784 · 1,251 participants · Start Nov 11, 2017 · Primary completion Jul 9, 2020
Drug: Varenicline; Nicotine patch · For: Tobacco Dependence
Sites: Madison, Wisconsin; Milwaukee, Wisconsin
- Pharmacogenetics of Nicotine Addiction TreatmentPivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT01314001 · 1,246 participants · Start Dec 2010 · Primary completion Dec 2013
Drug: Varenicline; Placebo and 1 more · For: Nicotine Addiction
Sites: Buffalo, New York; Philadelphia, Pennsylvania; Houston, Texas · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sneezing749
- nausea586
- drug ineffective473
- vomiting398
- depression364
- headache311
- nasal discomfort263
- product delivery mechanism issue252
- rhinorrhoea236
- suicidal ideation225
- nightmare213
- abnormal dreams212
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 68 |
| 2008 | 839 |
| 2009 | 478 |
| 2010 | 187 |
| 2011 | 45 |
| 2012 | 66 |
| 2013 | 31 |
| 2014 | 33 |
| 2015 | 53 |
| 2016 | 40 |
| 2017 | 45 |
| 2018 | 51 |
| 2019 | 65 |
| 2020 | 54 |
| 2021 | 53 |
| 2022 | 654 |
| 2023 | 806 |
| 2024 | 1,555 |
| 2025 | 649 |
| 2026 | 459 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tyrvaya (Varenicline Tartrate)
2024 spending
$71.7M
Beneficiaries
28,409
90,460 claims
Per beneficiary
$2,525
$76.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $283,569 |
| 2022 | $11,557,368 |
| 2023 | $37,471,489 |
| 2024 | $71,731,632 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial.
Evins AE, Cather C, Reeder HT, et al. · JAMA 2025 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Cytisine for smoking cessation: A systematic review and meta-analysis.
Ofori S, Lu C, Olasupo OO, et al. · Drug Alcohol Depend 2023 · Meta-Analysis, Systematic Review
- Interventions for quitting vaping.
Butler AR, Lindson N, Livingstone-Banks J, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.
Courtney RJ, McRobbie H, Tutka P, et al. · JAMA 2021 · Comparative Study, Equivalence Trial
- Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM, Benowitz NL, West R, et al. · Lancet 2016 · Multicenter Study, Randomized Controlled Trial
- Effectiveness of nurse-led smoking cessation interventions in smoking patients: A systematic review and network meta-analysis of randomized controlled trials.
Zhang G, Zhou J, Xu Y, et al. · Int J Nurs Stud 2025 · Systematic Review, Network Meta-Analysis
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.